Development of Transdiagnostic Single-session Treatment
Study Details
Study Description
Brief Summary
The goal of this clinical trial is to test a single session treatment program in primary care patients with anxiety and/or depression and/or stress-related issues. The main questions it aims to answer is:
-
Will the transdiagnostic treatment program decrease symptoms of depression/anxiety/stress?
-
Will the transdiagnostic treatment program decrease transdiagnostic risk factors?
-
Will the transdiagnostic treatment program decrease the measured risk factors equally?
-
Will the transdiagnostic treatment program impact patients with anxiety, depression or stress disorders equally?
-
Will the transdiagnostic treatment program have long term (6 months post-treatment) effect on transdiagnostic risk factors?
-
Will the transdiagnostic treatment program have long term (6 months post-treatment) effect on anxiety, depression, or stress-symptoms?
-
Have the participants been able to generalize the skills taught in the program(qualitative)?
-
Within group that were treated with single-session treatment and recieved additional care before follow-up, was there a difference in outcome?
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
The study investigates the effect of a single-session, 4 hour, transdiagnostic treatment for primary care patientst with depression, anxiety or stress.
The treatment includes, interoceptive exposure, behavioral activation, mindfulness, defusion and psycho-education about emotions.
The study is conducted in a clinical setting in northern sweden and follows up results at 3 weeks and 6 months post treatment.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
No Intervention: Control group
|
|
Experimental: Treatment group Transdiagnostic single-session treatment |
Behavioral: Transdiagnostic single-session treatment
Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
|
Outcome Measures
Primary Outcome Measures
- Anxiety, Depression and Stress symptoms post-treatment [3 weeks post-treatment]
Measured using DASS-21
- Anxiety, Depression and Stress symptoms follow-up [6 months post-treatment]
Measured using DASS-21
- Anxiety sensitivity post-treatment [3 weeks post-treatment]
Measured using BSQ, fear of bodily sensations related to anxiety
- Anxiety sensitivity follow-up [6 months post-treatment]
Measured using BSQ, fear of bodily sensations related to anxiety
- Experiential avoidance post-treatment [3 weeks post-treatment]
Measured using AFQ-Y8, psychological flexibility
- Experiential avoidance follow-up [6 months post-treatment]
Measured using AFQ-Y8, psychological flexibility
- Mindfulness post-treatment [3 weeks post-treatment]
Measured using FFMQ, mindfulness
- Mindfulness follow-up [6 months post-treatment]
Measured using FFMQ, mindfulness
- Alexithymia post-treatment [3 weeks post-treatment]
Measured using TAS-20, mindfulness
- Alexithymia follow-up [6 months post-treatment]
Measured using TAS-20, mindfulness
- Generalization [6 months post-treatment]
Qualitative interview with a few selected patients to review their experience of the treatment, its effectiveness and their ability to use the techniques taught.
Secondary Outcome Measures
- Additional treatment [6 months post-treatment]
It will be recorded if patients sought additional care after single-session treatment as well as type of care.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Meet the criteria for anxiety, mood disorder, or stress diagnosis
-
Symptoms are mild to moderate in severity
Exclusion Criteria:
-
Already in ongoing psychotherapy
-
Within a month commenced pharmaceutical treatment that will likely impact mood or psychological functioning and is not deemed to be on a stable dose
-
Has a comorbid personality disorder
-
Has a risk of suicide deemed other than low
-
Has other severe psychological disorders outside the scope of primary care
-
Is in a severely stressful social situation deemed incompatible with psychotherapy
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Luleå Tekniska Universitet
- Region Norrbotten
Investigators
- Principal Investigator: John Näsling, Master, Luleå tekniska universitet/Region Norrbotten
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 275863